Showing 15 posts of 17 posts found.


Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …

Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent

February 4, 2019
Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent

It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …


Sanofi/Regeneron forced to slash price in wake of slow sales

May 1, 2018
Research and Development, Sales and Marketing Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical, praluent

Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …


Sanofi and Regeneron reveal strong data and a price drop for Praluent

March 12, 2018
Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent

Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …

Sanofi and Regeneron posts positive Praluent cholesterol data

June 12, 2017
Research and Development, Sales and Marketing Regeneron, Sanofi, praluent

Sanofi and Regeneron were able to update its PCSK9 therapy Praluent with the positive data showing it could reduce levels …

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …


Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …


Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …


Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015
Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …


Sanofi and Regeneron given European nod for Praluent

September 28, 2015
Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent

The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent.  The heart drug is …

ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015
Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …

Sanofi Regeneron

FDA and EMA approve heart drug Praluent

July 27, 2015
Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent

The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …


Praluent scores positive trial results in Japan

July 9, 2015
Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent

Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …

Sanofi image

Sanofi and Amgen cholesterol drugs shine

March 16, 2015
Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent

Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …

Latest content